triazoles has been researched along with rilpivirine in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Back, D; Else, L; Hughes, A; Khoo, S; Siccardi, M; Tjia, J; Watson, V | 1 |
| Lacombe, K; Surgers, L | 1 |
| McGowan, I | 1 |
| Feng, M; Grobler, JA; Hazuda, DJ; Lai, MT; Miller, MD; Wang, D | 1 |
| Blair, W; Feng, M; Grobler, J; Hazuda, DJ; Lai, MT; Miller, MD; Sachs, NA; Xu, M | 1 |
| Akram, A; Ambrose, Z; Hughes, SH; Melody, K; Pauly, GT; Schneider, JP; Smith, SJ | 1 |
| Marzinke, MA; Parsons, TL | 1 |
| Belarbi, L; Chaix, ML; Dulioust, E; Duvivier, C; Ghosn, J; Launay, O; Lê, MP; Mahjoub, N; Peytavin, G; Salmon, D; Viard, JP | 1 |
| Álvarez, H; Llibre, JM; Yzusqui, M | 1 |
| Andreoni, M; Antinori, A; Bagnarelli, P; Borghi, V; Bruzzone, B; Callegaro, AP; De Gennaro, M; Gianotti, N; Maffongelli, G; Maggiolo, F; Saladini, F; Sterrantino, G; Vergori, A; Zaccarelli, M; Zazzi, M | 1 |
| Alves Saldanha, S; André, P; Buclin, T; Cavassini, M; Choong, E; Courlet, P; Csajka, C; Decosterd, LA; Desfontaine, V; Günthard, HF; Marzolini, C | 1 |
| Hewlett, K; Hughes, SH; Pauly, GT; Schneider, JP; Smith, SJ | 1 |
| Asante-Appiah, E; Feng, M; Graham, D; Hazuda, DJ; Hwang, C; Kumar, S; Lai, MT; Martin, EA; Ngo, W; Sklar, P | 1 |
| Arnold, E; Bijnens, M; Das, K; De Wijngaert, B; Herdewijn, P; Martinez, SE; Nguyen, H; Pannecouque, C; Schols, D; Singh, AK; Uyttersprot, K | 1 |
4 review(s) available for triazoles and rilpivirine
| Article | Year |
|---|---|
Hepatoxicity of new antiretrovirals: a systematic review.
Topics: Anti-Retroviral Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Cyclohexanes; Darunavir; Heterocyclic Compounds, 3-Ring; Humans; Maraviroc; Nitriles; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Rilpivirine; Sulfonamides; Triazoles | 2013 |
An overview of antiretroviral pre-exposure prophylaxis of HIV infection.
Topics: Adenine; Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; Female; HIV Infections; Humans; Male; Maraviroc; Medication Adherence; Nitriles; Organophosphonates; Pre-Exposure Prophylaxis; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Triazoles | 2014 |
Clinical Impact of Virological Failure and Resistance Analysis Definitions used in Pivotal Clinical Trials of Initial Antiretroviral Treatment: A Systematic Review
Topics: Amides; Anti-Retroviral Agents; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Quinolones; Rilpivirine; RNA, Viral; Triazoles; Viral Load | 2018 |
Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; In Vitro Techniques; Pyridones; Rilpivirine; Triazoles | 2020 |
10 other study(ies) available for triazoles and rilpivirine
| Article | Year |
|---|---|
Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.
Topics: Analysis of Variance; Anti-HIV Agents; Chromatography, High Pressure Liquid; Cyclohexanes; Drug Stability; Maraviroc; Nitriles; Pyridazines; Pyrimidines; Reproducibility of Results; Rilpivirine; Sensitivity and Specificity; Tandem Mass Spectrometry; Triazoles | 2010 |
In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HEK293 Cells; HIV-1; Humans; Mutation; Nitriles; Pyridazines; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Selection, Genetic; Triazoles | 2015 |
Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Dosage Calculations; Drug Resistance, Viral; Gene Expression; HEK293 Cells; HIV Reverse Transcriptase; HIV-1; Humans; Inhibitory Concentration 50; Mutation; Pyridones; Rilpivirine; Triazoles | 2016 |
Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.
Topics: Dose-Response Relationship, Drug; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Inhibitory Concentration 50; Models, Molecular; Mutation; Pyridones; Reverse Transcriptase Inhibitors; Rilpivirine; Triazoles; Virus Replication | 2016 |
Development and validation of a liquid chromatographic-tandem mass spectrometric method for the multiplexed quantification of etravirine, maraviroc, raltegravir, and rilpivirine in human plasma and tissue.
Topics: Chromatography, Liquid; Cyclohexanes; Humans; Maraviroc; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium; Reproducibility of Results; Rilpivirine; Tandem Mass Spectrometry; Triazoles | 2016 |
Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.
Topics: Adult; Anti-HIV Agents; Body Fluids; Cervix Uteri; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Prospective Studies; Raltegravir Potassium; Rilpivirine; Semen; Triazoles; Vagina; Viral Load | 2017 |
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Treatment Outcome; Triazoles | 2019 |
Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HI
Topics: Amides; Anti-Retroviral Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Limit of Detection; Linear Models; Piperazines; Pyridones; Reference Standards; Reproducibility of Results; Rilpivirine; Tandem Mass Spectrometry; Triazoles | 2020 |
Structure-based non-nucleoside inhibitor design: Developing inhibitors that are effective against resistant mutants.
Topics: Anti-HIV Agents; Binding Sites; Drug Design; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Dynamics Simulation; Mutation; Pyridones; Pyrimidines; Rilpivirine; Triazoles | 2021 |
Cryo-EM structures of wild-type and E138K/M184I mutant HIV-1 RT/DNA complexed with inhibitors doravirine and rilpivirine.
Topics: Anti-HIV Agents; Cryoelectron Microscopy; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Mutation; Nitriles; Protein Conformation; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Triazoles | 2022 |